BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.

Employees - 44, CEO - Qiu Min, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -41.3, Piotroski Score(max is 10): 1, Working Capital: $-4292000, Total Assets: $14606000, Retained Earnings: $-411439000, EBIT: -8014000, Total Liabilities: $50631000, Revenue: $0

AryaFin Target Price - $0.18 - Current Price $ - Analyst Target Price $